Harpoon Therapeutics Appoints Omer Siddiqui as VP Development Operations and Project Management. SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Omer Siddiqui as Vice President, Development Operations and Project Management. Mr. Siddiqui joins Harpoon most recently from Alector, where he served as Vice President, Head of Development Operations.



“I am delighted that Omer is joining Harpoon to lead development operations to support our expanding clinical portfolio,” said Jerry McMahon, Ph.D., President and Chief Executive Officer of Harpoon Therapeutics. “His extensive background and experience in oncology drug clinical development, business operations, portfolio strategy and project management will be an asset as we continue to advance our product candidate pipeline of T cell engagers for the treatment of solid tumor and hematologic malignancies.”

Omer Siddiqui is a well-recognized R&D leader in oncology with expertise in both early and late-stage clinical development in multiple therapeutic areas. As head of development operations at Alector, he led clinical development planning and strategy to progress three antibody programs from research to the clinic that resulted in a substantial pharma partnership. He has also built high-performing clinical groups to oversee ongoing and future clinical programs. Previous career experience includes clinical operations management at Allakos, Genentech and INC Research. Mr. Siddiqui received an MSc in Biotechnology at Johns Hopkins University and a BSc in Biology from the University of Western Ontario.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1 trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin including ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase1/2 trial in the second half of 2020. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com .

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, the timing of development milestones for product candidates, and the anticipated potential impacts to Harpoon Therapeutics’ business from the ongoing COVID-19 pandemic. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts:

Harpoon Therapeutics, Inc.

Georgia Erbez

Chief Financial Officer

650-443-7400

media@harpoontx.com

Westwicke ICR

Robert H. Uhl

Managing Director

858-356-5932

robert.uhl@westwicke.com



